Similar articles

• Releasing the Brakes on Cancer Immunotherapy.

  Ribas A. Ribas A. N Engl J Med. 2015 Oct 15;373(16):1490-2. doi: 10.1056/NEJMp1510079. Epub 2015 Sep 8. N Engl J Med. 2015. PMID: 26348216 No abstract available.
• Specific CD8(+) T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis.

  Moreno-Cubero E, Larrubia JR. Moreno-Cubero E, et al. World J Gastroenterol. 2016 Jul 28;22(28):6469-83. doi: 10.3748/wjg.v22.i28.6469. World J Gastroenterol. 2016. PMID: 27605882 Free PMC article. Review.
• [Physiopathological mechanisms of immune-related adverse events induced by anti-CTLA-4, anti-PD-1 and anti-PD-L1 antibodies in cancer treatment].

  Passat T, Touchefeu Y, Gervois N, Jarry A, Bossard C, Bennouna J. Passat T, et al. Bull Cancer. 2018 Nov;105(11):1033-1041. doi: 10.1016/j.bulcan.2018.07.005. Epub 2018 Sep 21. Bull Cancer. 2018. PMID: 30244981 Review. French.
• Immune checkpoints and their inhibition in cancer and infectious diseases.

  Dyck L, Mills KHG. Dyck L, et al. Eur J Immunol. 2017 May;47(5):765-779. doi: 10.1002/eji.201646875. Epub 2017 Apr 24. Eur J Immunol. 2017. PMID: 28393361 Review.
• Nouvelles perspectives dans l’immunothérapie des cancers.

  Caux C, Bay JO. Caux C, et al. Bull Cancer. 2018 Dec;105 Suppl 1:S1-S2. doi: 10.1016/S0007-4551(18)30384-9. Bull Cancer. 2018. PMID: 30595190 French.